AZD5153 clinical trials
Also written AZD5153.
How each study uses AZD5153 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the AZD5153 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AZD5153
- 2
Studies by the year they started
3 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Acerta Pharma BV (1) · AstraZeneca (1) · Beat AML, LLC (1)
Often tested with
Tested in the same studies.
Danvatirsen (1) · Ceralasertib (1) · Magrolimab (1) · Samalizumab (1) · BI 836858 (1) · Cytarabine (1) · Azacitidine (1) · Enasidenib (1)
Studies
Open first, then newest update. How each study uses AZD5153 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingPhase 2/3Beat AML, LLCNCT03013998Written as AZD5153 (BAML-16-001-S10)
- Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study)CompletedPhase 1Acerta Pharma BVNCT03527147Written as AZD5153
- AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including LymphomasCompletedPhase 1AstraZenecaNCT03205176Written as AZD5153
Codes
What other systems call AZD5153 · ClinicalTrials.gg INT000731
- MeSH (NLM) C000621120AZD5153One source NLM
- UNII (FDA) C7C7U6YEAOAZD-5153Confirmed FDA, NLM
- NCI Thesaurus C151943Bivalent BRD4 Inhibitor AZD5153One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000621120 | AZD5153 | One source NLM |
| UNII (FDA) | C7C7U6YEAO | AZD-5153 | Confirmed FDA, NLM |
| NCI Thesaurus | C151943 | Bivalent BRD4 Inhibitor AZD5153 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.